Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation - PubMed (original) (raw)
Case Reports
. 2017 Feb;15(2):142-147.
doi: 10.6004/jnccn.2017.0016.
Affiliations
- PMID: 28188185
- DOI: 10.6004/jnccn.2017.0016
Case Reports
Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation
Jun Gong et al. J Natl Compr Canc Netw. 2017 Feb.
Abstract
Recent clinical evidence has demonstrated that microsatellite instability (MSI) or defective mismatch repair (MMR) and high tumor mutational load can predict response to the programmed cell death 1 (PD-1) receptor inhibitor pembrolizumab in metastatic colorectal cancer (mCRC). Mutations in polymerase ε (POLE), a DNA polymerase involved in DNA replication and repair, contribute to an ultramutated but microsatellite stable (MSS) phenotype in colorectal tumors that is uniquely distinct from MSI tumors. This report presents the first case in the literature describing a clinical response to pembrolizumab in an 81-year-old man with treatment-refractory mCRC characterized by an MSS phenotype and POLE mutation identified on genomic profiling by next-generation sequencing. On tumor immunostaining, a large amount of CD8-positive tumor infiltrating lymphocytes (TILs) were present, with >90% of these expressing PD-1. More than 99% of PD-L1 expression was identified on nontumor cells in the tumor microenvironment that were close to the PD-1-positive CD8 TILs. mCRC tumors harboring POLE mutations represent a hypermutated phenotype that may predict response to anti-PD-1 therapy.
Copyright © 2017 by the National Comprehensive Cancer Network.
Similar articles
- Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.
Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D'Andrea AD, Wu CJ, Matulonis UA, Konstantinopoulos PA. Howitt BE, et al. JAMA Oncol. 2015 Dec;1(9):1319-23. doi: 10.1001/jamaoncol.2015.2151. JAMA Oncol. 2015. PMID: 26181000 - Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
Song Z, Cheng G, Xu C, Wang W, Shao Y, Zhang Y. Song Z, et al. Lung Cancer. 2018 Apr;118:57-61. doi: 10.1016/j.lungcan.2018.02.004. Epub 2018 Feb 6. Lung Cancer. 2018. PMID: 29572003 - The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT, de Souza P, Lim SH, Singh P, Chua W, Ng W, Spring KJ. Toh JWT, et al. Clin Colorectal Cancer. 2016 Dec;15(4):285-291. doi: 10.1016/j.clcc.2016.07.007. Epub 2016 Jul 22. Clin Colorectal Cancer. 2016. PMID: 27553906 Review. - A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer.
Kim JH, Kim SY, Baek JY, Cha YJ, Ahn JB, Kim HS, Lee KW, Kim JW, Kim TY, Chang WJ, Park JO, Kim J, Kim JE, Hong YS, Kim YH, Kim TW. Kim JH, et al. Cancer Res Treat. 2020 Oct;52(4):1135-1144. doi: 10.4143/crt.2020.218. Epub 2020 Apr 24. Cancer Res Treat. 2020. PMID: 32340084 Free PMC article. Clinical Trial.
Cited by
- Recent developments in immunotherapy for gastrointestinal tract cancers.
Chong X, Madeti Y, Cai J, Li W, Cong L, Lu J, Mo L, Liu H, He S, Yu C, Zhou Z, Wang B, Cao Y, Wang Z, Shen L, Wang Y, Zhang X. Chong X, et al. J Hematol Oncol. 2024 Aug 9;17(1):65. doi: 10.1186/s13045-024-01578-x. J Hematol Oncol. 2024. PMID: 39123202 Free PMC article. Review. - Precision Medicine in the Era of Genetic Testing: Microsatellite Instability Evolved.
Ioffe D, McSweeny M, Hall MJ. Ioffe D, et al. Clin Colon Rectal Surg. 2023 Jul 25;37(3):157-171. doi: 10.1055/s-0043-1770385. eCollection 2024 May. Clin Colon Rectal Surg. 2023. PMID: 38617845 Free PMC article. Review. - Circular RNA circNCOA3 promotes tumor progression and anti-PD-1 resistance in colorectal cancer.
Chen DL, Chen N, Sheng H, Zhang DS. Chen DL, et al. Cancer Drug Resist. 2024 Mar 13;7:9. doi: 10.20517/cdr.2023.151. eCollection 2024. Cancer Drug Resist. 2024. PMID: 38510750 Free PMC article. - Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment.
Gmeiner WH. Gmeiner WH. Cancers (Basel). 2024 Mar 2;16(5):1029. doi: 10.3390/cancers16051029. Cancers (Basel). 2024. PMID: 38473386 Free PMC article. Review. - Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer.
Takei S, Tanaka Y, Lin YT, Koyama S, Fukuoka S, Hara H, Nakamura Y, Kuboki Y, Kotani D, Kojima T, Bando H, Mishima S, Ueno T, Kojima S, Wakabayashi M, Sakamoto N, Kojima M, Kuwata T, Yoshino T, Nishikawa H, Mano H, Endo I, Shitara K, Kawazoe A. Takei S, et al. J Immunother Cancer. 2024 Feb 8;12(2):e008210. doi: 10.1136/jitc-2023-008210. J Immunother Cancer. 2024. PMID: 38336371 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous